id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-1333-0028,FDA,FDA-2021-N-1333,Reference 3--Medical Gas CPGM,Supporting & Related Material,Background Material,2024-06-18T04:00:00Z,2024,6,,,2024-06-18T15:24:17Z,,0,0,09000064865bd76c
FDA-2021-N-1333-0031,FDA,FDA-2021-N-1333,Reference 6--FRIA Medical Gases,Supporting & Related Material,Background Material,2024-06-18T04:00:00Z,2024,6,,,2024-06-18T15:24:39Z,,0,0,09000064865bd771
FDA-2021-N-1333-0025,FDA,FDA-2021-N-1333,"Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases",Rule,Final Rule,2024-06-18T04:00:00Z,2024,6,2024-06-18T04:00:00Z,,2024-06-20T12:33:21Z,2024-13190,0,0,09000064865bc84f
FDA-2021-N-1333-0027,FDA,FDA-2021-N-1333,Reference 2--Med Gas - Container Closure - OMQ White Paper,Supporting & Related Material,Background Material,2024-06-18T04:00:00Z,2024,6,,,2024-06-18T15:24:14Z,,0,0,09000064865bd76b
FDA-2021-N-1333-0026,FDA,FDA-2021-N-1333,Reference 1--Certification Process Draft Guidance,Supporting & Related Material,Background Material,2024-06-18T04:00:00Z,2024,6,,,2024-06-18T15:24:11Z,,0,0,09000064865bd76a
FDA-2021-N-1333-0029,FDA,FDA-2021-N-1333,Reference 4--Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application,Supporting & Related Material,Background Material,2024-06-18T04:00:00Z,2024,6,,,2024-06-18T15:24:22Z,,0,0,09000064865bd76f
FDA-2021-N-1333-0030,FDA,FDA-2021-N-1333,Reference 5--Postmarketing Safety Reporting Draft Guidance,Supporting & Related Material,Background Material,2024-06-18T04:00:00Z,2024,6,,,2024-06-18T15:24:36Z,,0,0,09000064865bd770